Informações de Savara Inc

Mais detalhes de Savara Inc Empresa

Savara Inc. is a clinical-stage biopharmaceutical company, which is focused on rare respiratory diseases. The Company’s lead program, molgramostim nebulizer solution (molgramostim), is an inhaled biologic, specifically an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase III development for autoimmune pulmonary alveolar proteinosis (aPAP). Molgramostim is an inhaled formulation of recombinant human GM-CSF and is being developed for the treatment of aPAP. Molgramostim nebulizer solution is administered once daily by inhalation via a high efficiency nebulizer, the eFlow Nebulizer System (PARI Pharma GmbH). Pulmonary alveolar proteinosis (PAP) is a rare lung disease characterized by the accumulation of surfactant in the alveoli (or air sacs) of the lungs. The Company is engaged in the advancement of the molgramostim aPAP program and the Phase III IMPALA-2 clinical trial and outsourcing capital-intensive operations.



Código da empresaSVRA

Nome da EmpresaSavara Inc

Data de listagemJun 25, 2001

CEOMr. Matthew (Matt) Pauls, J.D.

Número de funcionários59

Tipo de títulosOrdinary Share

Fim do ano fiscalJun 25

Endereço6836 Bee Cave Road

CidadeAUSTIN

Bolsa de valoresNASDAQ Global Select Consolidated

PaísUnited States of America

Código postal78746

Telefone151285113796

Sitehttps://savarapharma.com/

Código da empresaSVRA

Data de listagemJun 25, 2001

CEOMr. Matthew (Matt) Pauls, J.D.

Executivos da empresa Savara Inc



Nome

Nome/Posição

Posição

Ações detidas

Variação

Mr. David A. Ramsay

Independent Director

2.47M

-0.70%

Dr. Joseph S. (Joe) Mccracken, Ph.D.

Lead Independent Director

220.84K

+4.74%

Ms. Anne Erickson

Chief Business Officer

194.99K

+72.18%

Mr. Braden Parker

Chief Commercial Officer

105.00K

+23.53%

Mr. Robert Matthew (Rob) Lutz

Chief Operating Officer

101.74K

+64.79%

Mr. Nevan Charles Elam, J.D.

Independent Director

--

Mr. Richard J. (Rick) Hawkins

Independent Director

--

Mr. David L. Lowrance, CPA

Chief Financial and Administrative Officer, Secretary

--

Mr. Matthew (Matt) Pauls, J.D.

Chairman of the Board, Chief Executive Officer

--

Dr. Raymond Dennis (Ray) Pratt, M.D.

Chief Medical Officer

--

Ver Mais

Nome

Nome/Posição

Posição

Ações detidas

Variação

Mr. David A. Ramsay

Independent Director

2.47M

-0.70%

Dr. Joseph S. (Joe) Mccracken, Ph.D.

Lead Independent Director

220.84K

+4.74%

Ms. Anne Erickson

Chief Business Officer

194.99K

+72.18%

Mr. Braden Parker

Chief Commercial Officer

105.00K

+23.53%

Mr. Robert Matthew (Rob) Lutz

Chief Operating Officer

101.74K

+64.79%

Mr. Nevan Charles Elam, J.D.

Independent Director

--

Detalhamento da receita

Sem dados

Sem dados

Por Empresa

Por Região

Sem dados

Distribuição de ações

Atualizado em: dom, 2 de nov

Investidores

Tipos de investidores

Investidores

Proporção

New Enterprise Associates (NEA)

12.44%

Bain Capital Life Sciences Investors, LLC

8.95%

Deerfield Management Company, L.P.

6.90%

TCG Crossover Management, LLC

6.29%

Frazier Life Sciences Management, L.P.

5.83%

Outro

59.59%

Investidores

Proporção

New Enterprise Associates (NEA)

12.44%

Bain Capital Life Sciences Investors, LLC

8.95%

Deerfield Management Company, L.P.

6.90%

TCG Crossover Management, LLC

6.29%

Frazier Life Sciences Management, L.P.

5.83%

Outro

59.59%

Tipos de investidores

Investidores

Proporção

Investment Advisor

29.98%

Hedge Fund

20.01%

Venture Capital

18.26%

Investment Advisor/Hedge Fund

14.30%

Private Equity

5.83%

Corporation

3.46%

Individual Investor

2.45%

Research Firm

0.47%

Bank and Trust

0.27%

Outro

4.97%

Participação acionária institucional



Atualizado em: qua, 1 de out

Período do relatório

N.º de instituições

Ações detidas

Proporção

Variação

2025Q3

286

169.85M

86.94%

-21.45M

2025Q2

295

181.81M

105.19%

-8.48M

2025Q1

306

176.74M

102.29%

-9.64M

2024Q4

294

173.80M

101.27%

-5.45M

2024Q3

274

169.68M

103.28%

+3.87M

2024Q2

257

157.29M

95.89%

+28.15M

2024Q1

230

131.01M

94.21%

-92.17K

2023Q4

197

123.19M

91.03%

-2.15M

2023Q3

177

120.11M

89.27%

+14.67M

2023Q2

170

92.45M

81.05%

-2.68M

Ver Mais

Atividade dos acionistas



Nome

Ações detidas

Proporção

Variação

Var. %

Data

New Enterprise Associates (NEA)

24.47M

14.16%

--

Jun 30, 2025

Bain Capital Life Sciences Investors, LLC

17.60M

10.18%

--

Jun 30, 2025

Deerfield Management Company, L.P.

7.96M

4.61%

--

Jun 30, 2025

TCG Crossover Management, LLC

12.36M

7.15%

--

Jun 30, 2025

Frazier Life Sciences Management, L.P.

11.46M

6.63%

--

Jun 30, 2025

Vestal Point Capital, LP

11.02M

6.37%

+15.00K

+0.14%

Jun 30, 2025

VR Adviser, LLC

8.88M

5.14%

+5.63M

+172.72%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

8.54M

4.94%

-164.33K

-1.89%

Jun 30, 2025

Nantahala Capital Management, LLC

8.33M

4.82%

+250.00K

+3.10%

Jun 30, 2025

The Vanguard Group, Inc.

8.43M

4.88%

+334.73K

+4.13%

Jun 30, 2025

Ver Mais

ETFs Relacionados



Atualizado em: qui, 6 de nov

Nome

Proporção

Virtus LifeSci Biotech Clinical Trials ETF

1.14%

Texas Capital Texas Small Cap Equity Index ETF

0.21%

iShares Micro-Cap ETF

0.08%

Invesco Nasdaq Biotechnology ETF

0.06%

ProShares Ultra Nasdaq Biotechnology

0.06%

Texas Capital Texas Equity Index ETF

0.05%

iShares Biotechnology ETF

0.03%

iShares Russell 2000 Growth ETF

0.03%

ProShares UltraPro Russell2000

0.01%

iShares Morningstar Small-Cap ETF

0.01%

Ver Mais

Virtus LifeSci Biotech Clinical Trials ETF

Proporção1.14%

Texas Capital Texas Small Cap Equity Index ETF

Proporção0.21%

iShares Micro-Cap ETF

Proporção0.08%

Invesco Nasdaq Biotechnology ETF

Proporção0.06%

ProShares Ultra Nasdaq Biotechnology

Proporção0.06%

Texas Capital Texas Equity Index ETF

Proporção0.05%

iShares Biotechnology ETF

Proporção0.03%

iShares Russell 2000 Growth ETF

Proporção0.03%

ProShares UltraPro Russell2000

Proporção0.01%

iShares Morningstar Small-Cap ETF

Proporção0.01%

Dividendo



Um total de 0.00 USD foi distribuído em dividendos nos últimos 5 anos.

Data

Dividendo

Data de registro

Data de pagamento

Data ex-dividendo

Sem dados

Desdobramento de ações



Data

Tipo

Proporção

Sem dados

Data

Tipo

Proporção

Sem dados